NCT03098589 2025-03-30Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)CelgeneCompleted1,149 enrolled
NCT02921828 2022-07-05A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mgCelgeneCompleted1,149 enrolled
NCT02921802 2022-06-14A Study of Special Use Results Surveillance of Revlimid 5mg CapsulesCelgeneCompleted4,626 enrolled
NCT02922543 2022-06-14A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of UseCelgeneCompleted361 enrolled
NCT00005660 2008-03-04The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive DiseasesNational Institutes of Health Clinical Center (CC)Completed130 enrolled